After REMS: An Interview With Amgen’s Paul Seligman
Health care reform means a lot of things for the pharmaceutical industry. Will it also mean the end of REMS? The former head of FDA’s drug safety office thinks that is a question worth asking.
Health care reform means a lot of things for the pharmaceutical industry. Will it also mean the end of REMS? The former head of FDA’s drug safety office thinks that is a question worth asking.